This is what happened on January 13th. CytoDyn
Post# of 148292
CytoDyn Cancels Webcast and Live Q/A Scheduled for Today
Press Release | 01/13/2022
CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced it has canceled its webcast scheduled for today, Thursday, January 13, 2022 and will provide an update at a future date.